A naukri.com initiative
Gritdaily
2w
295
Image Credit: Gritdaily
From Survivor to Innovator: Ted Belleza and the URO-1 Team’s Mission to Improve Prostate Cancer Diagnosis
- Prostate cancer survivor and founder of URO-1, Ted Belleza, came out of retirement to improve the technology used to collect the biopsies essential for diagnosis.
- URO-1’s innovative products include the SUREcore needle, which increases biopsy tissue volume with high tissue quality, and the coreCARE specimen retrieval cradle.
- Initial results from a multicenter clinical study indicate that the use of SUREcore and coreCARE significantly increases both the quantity and quality of biopsy samples to allow for more accurate prostate cancer diagnoses and reduce the need for repeat procedures.
- Up to 40% of current prostate biopsy technologies either overestimate or underestimate the severity of the disease.
- URO-1’s patented, FDA-cleared technology is ready for rapid market expansion and has secured $250,000 in funding from the North Carolina Biotechnology Center.
- The company has established a Clinical Trial Agreement with Duke University to ensure rigorous validation of its products.
- Collaborations with prominent urology groups, including Georgia Urology and New River Urology, further validate URO-1’s technology and its potential impact on improving biopsy accuracy and patient outcomes.
- The team at URO-1 isn’t just innovating for the sake of innovation—they are focused on transforming an outdated standard and an archaic inefficient process into a premium solution that sets new benchmarks in biopsy technology.
- URO-1 Founders include Philip Allred as V.P. of R&D, Jack Snoke as V.P. of Applications Development and Chloe Chan as Chief Financial Officer.
- URO-1’s goal is to improve outcomes and raise the value of the product by innovating and improving clinical outcomes.
Read Full Article
17 Likes
For uninterrupted reading, download the app